Schizophrenia Research-Cognition最新文献

{"title":"Designing smartphone-based cognitive assessments for schizophrenia: Perspectives from a multisite study","authors":"Aishwarya Raje ,&nbsp;Abhijit R. Rozatkar ,&nbsp;Urvakhsh Meherwan Mehta ,&nbsp;Ritu Shrivastava ,&nbsp;Ameya Bondre ,&nbsp;Manaal Amir Ahmad ,&nbsp;Anshika Malviya ,&nbsp;Yogendra Sen ,&nbsp;Deepak Tugnawat ,&nbsp;Anant Bhan ,&nbsp;Tamonud Modak ,&nbsp;Nabagata Das ,&nbsp;Srilakshmi Nagendra ,&nbsp;Erlend Lane ,&nbsp;Juan Castillo ,&nbsp;John A. Naslund ,&nbsp;John Torous ,&nbsp;Soumya Choudhary","doi":"10.1016/j.scog.2025.100347","DOIUrl":"10.1016/j.scog.2025.100347","url":null,"abstract":"<div><h3>Introduction</h3><div>Cognitive deficits represent a core symptom of schizophrenia and a principal contributor to illness disability, yet evaluating cognition in routine clinical settings is often not feasible as cognitive assessments take longer than a standard doctor's visit. Using smartphones to assess cognition in schizophrenia offers the advantages of convenience in that patients can complete assessments outside of the clinic, temporality in that longitudinal trends can be identified, and contextuality in that cognitive scores can be interpreted with other measures captured by the phone (e.g. sleep). The current study aims to design a battery of cognitive assessments corresponding to the MATRICs Consensus Battery of Cognition (MCCB), in partnership with people living with schizophrenia.</div></div><div><h3>Methodology</h3><div>Focus group discussions (FGDs) and interviews were conducted with people diagnosed with schizophrenia across three sites (Boston, Bhopal, and Bangalore) to help design, refine, and assess the proposed smartphone battery of cognitive tests on the mindLAMP app. Interviews were conducted between December 2023 and March 2024. Inductive thematic analysis was used to analyze data.</div></div><div><h3>Results</h3><div>Participants found the app and its proposed cognitive assessments to be acceptable, helpful, and easy to use. They particularly found the gamified nature of the cognitive tests to be appealing and engaging. However, they also proposed ways to further increase engagement by including more information about each cognitive test, more visual instructions, and more information about scoring. Across all sites, there were many similarities in themes.</div></div><div><h3>Discussion &amp; conclusion</h3><div>People living with schizophrenia, from different sites in the US and India, appear interested in using smartphone apps to track their cognition. Thematic analysis reinforces the importance of feedback and data sharing, although this presents a challenge, given the novel nature of smartphone-based cognitive measures that have not yet been standardized or validated.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100347"},"PeriodicalIF":2.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143242305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subjective cognition in schizophrenia and bipolar disorder: Investigation of group differences and associations with objective cognition and clinical characteristics using a novel measure of subjective cognition","authors":"Kristoffer Grimstad ,&nbsp;Håkon Sørensen ,&nbsp;Anja Vaskinn ,&nbsp;Christine Mohn ,&nbsp;Stine Holmstul Olsen ,&nbsp;Ole A. Andreassen ,&nbsp;Trine Vik Lagerberg ,&nbsp;Ingrid Melle ,&nbsp;Merete Glenne Øie ,&nbsp;Torill Ueland ,&nbsp;Beathe Haatveit","doi":"10.1016/j.scog.2025.100345","DOIUrl":"10.1016/j.scog.2025.100345","url":null,"abstract":"<div><div>Cognitive dysfunction is a well-documented feature of schizophrenia (SZ) and bipolar (BD) disorder. The person's subjective experience of cognitive difficulties is less investigated. Here we investigated subjective cognition in SZ and BD compared to healthy controls (HC).</div><div>Subjective and objective cognition were assessed in 91 SZ participants, 55 BD participants and 55 HC, applying a novel measure of subjective cognition, the self-assessed cognitive complaints scale (SACCS) and a clinically relevant neuropsychological test battery. The psychometric properties of SACCS were investigated. The relationship between subjective and objective cognition, and subjective cognition and clinical variables were explored in SZ and BD.</div><div>The SACCS showed adequate psychometric properties. Clinical groups reported significantly more cognitive complaints than HCs, without differences between SZ and BD. There were no significant associations between subjective and objective cognitive measures. There was a small trend association between subjective cognition and insight in SZ participants, and moderate sized associations between subjective cognition and general psychopathology and functioning in BD participants.</div><div>Although SZ participants are more cognitively impaired than BD participants, the two groups report similar levels of subjective cognitive complaints, with no association between subjective and objective cognition. Our results suggest that the expression of subjective cognition is associated with different clinical factors in SZ and BD.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100345"},"PeriodicalIF":2.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive impairments in first-episode psychosis patients with attenuated niacin response","authors":"MingLiang Ju ,&nbsp;Bin Long ,&nbsp;YanYan Wei ,&nbsp;XiaoChen Tang ,&nbsp;LiHua Xu ,&nbsp;RanPiao Gan ,&nbsp;HuiRu Cui ,&nbsp;YingYing Tang ,&nbsp;ZhengHui Yi ,&nbsp;HaiChun Liu ,&nbsp;ZiXuan Wang ,&nbsp;Tao Chen ,&nbsp;Jin Gao ,&nbsp;Qiang Hu ,&nbsp;LingYun Zeng ,&nbsp;ChunBo Li ,&nbsp;JiJun Wang ,&nbsp;HuanZhong Liu ,&nbsp;TianHong Zhang","doi":"10.1016/j.scog.2025.100346","DOIUrl":"10.1016/j.scog.2025.100346","url":null,"abstract":"<div><h3>Background</h3><div>Psychosis is a complex brain disorder with diverse biological subtypes influenced by various pathogenic mechanisms, which can affect treatment efficacy. The ANR(Attenuated Niacin Response) subtype is characterized by pronounced negative symptoms and functional impairments, suggesting a distinct clinical profile. However, research on the cognitive characteristics associated with the ANR subtype in drug-naïve first-episode psychosis(FEP) patients remains limited.</div></div><div><h3>Methods</h3><div>This observational study involved 54 FEP patients and 52 healthy controls(HC). Clinical psychopathology was assessed using the Positive and Negative Syndrome Scale(PANSS), while cognitive performance was evaluated through the Chinese version of the MATRICS Consensus Cognitive Battery(MCCB). Additionally, niacin response was measured using aqueous methylnicotinate patches, with responses quantified to classify participants into ANR or normal niacin response (NNR) groups.</div></div><div><h3>Results</h3><div>Among the FEP patients, 25.9 % were classified as having ANR, significantly higher than the 7.7 % in the HC group (<em>χ</em>^<em>2</em> = 6.247, <em>p</em> = 0.012). The ANR group exhibited more severe negative symptoms and higher total PANSS scores compared to the NNR group, with significant differences in cognitive performance on the Trail Making test and the Brief Visuospatial Memory Test-Revised. Correlation analyses revealed a significant positive relationship between overall symptom severity and niacin response, as well as between cognitive performance and niacin response, particularly for the Trail Making and Symbol coding tests.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that the ANR subtype in first-episode psychosis is linked to more severe negative symptoms and cognitive impairments. Targeted assessments and interventions for patients with ANR may improve treatment outcomes and enhance understanding of cognitive dysfunction in psychotic disorders.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100346"},"PeriodicalIF":2.3,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered theta band and theta/beta ratio in mismatch negativity associate with treatment effect in schizophrenia with auditory hallucinations","authors":"Qian Guo ,&nbsp;Zexin Zhao ,&nbsp;Wenzheng Wang ,&nbsp;Xiaonan Hu ,&nbsp;Hao Hu ,&nbsp;Yao Hu ,&nbsp;Lihua Xu ,&nbsp;Xu Liu ,&nbsp;Xiaohua Liu ,&nbsp;Guanjun Li ,&nbsp;Zhongying Shi ,&nbsp;Jijun Wang","doi":"10.1016/j.scog.2025.100344","DOIUrl":"10.1016/j.scog.2025.100344","url":null,"abstract":"<div><div>Evidence suggests that attenuated mismatch negative (MMN) waves have a close link to auditory verbal hallucinations (AVH) and their clinical outcomes, especially impaired neural oscillations such as θ, β representing attentional control. In current study, thirty patients with schizophrenia and AVH (SZ) and twenty-nine healthy controls (HC) underwent multi-feature MMN paradigm measurements including frequency and duration deviant stimuli (fMMN and dMMN). Clinical symptoms and MMN paradigm were followed up among SZ group after 8-week treatment. Results demonstrated that hallucinating patients exhibited attenuated dMMN amplitudes across Fz (p = 0.010), F1 (p = 0.020) and F2 (p = 0.014) electrodes, which were trendily recovered after treatment. Meanwhile, θ band and TBR at frontal fMMN and right temporal dMMN were significantly reduced in SZs. After treatment, SZs showed reduced scores of Hoffman's Auditory Hallucinations Rating Scale (AHRS), with a remarkable recovery in right temporal TBR of dMMN (p = 0.042) and a trending change in frontal TBR of fMMN (p = 0.090). The β band was decreased in dMMN (p = 0.035) by time. Additionally, P3 scores of Positive and Negative Syndrome Scale (PANSS) were negatively correlated with θ band of fMMN at baseline. Baseline scores of AHRS negatively predicted changes of dMMN amplitude after treatment, and changes of β band in left temporal dMMN predicted the reduction in scores of PANSS negative scale. These findings supported that deficits in θ oscillation and TBR during auditory attention process were crucial to clinical progression of schizophrenia with AVH.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100344"},"PeriodicalIF":2.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of reference markers in the speech of people with schizophrenia spectrum disorders: Evidence from two referential communication tasks manipulating common ground with the interaction partner","authors":"Amélie M. Achim ,&nbsp;Dominique Knutsen ,&nbsp;Marc-André Roy ,&nbsp;Souleymane Gadio ,&nbsp;Marion Fossard","doi":"10.1016/j.scog.2024.100343","DOIUrl":"10.1016/j.scog.2024.100343","url":null,"abstract":"<div><h3>Introduction</h3><div>People with schizophrenia spectrum disorders present with language dysfunctions, yet we know little about their use of reference markers (indefinite markers, definite markers, pronouns or names), a fundamental aspect of efficient speech production.</div></div><div><h3>Methods</h3><div>Twenty-five (25) participants with a recent-onset schizophrenia spectrum disorder (SZ) and 25 healthy controls (HC) completed two referential communication tasks. The tasks involved presenting to an interaction partner a series of movie characters (character identification task) and movie scenes composed of six images (narration task). A manipulation was introduced such that half of the movies could be considered as Likely-Known by the interaction partner, whereas the other half was Likely-Unknown. The analyses focused on the reference markers used to present the movie characters during the tasks.</div></div><div><h3>Results</h3><div>During the character identification task, the SZ group used fewer names and more pronouns than the HC. During the narration task, the SZ group used fewer names and more definite references when initially introducing the main story characters, while no group effect emerged for subsequent mentions of the characters. The observed effects of conditions were generally present across both groups, except for a lesser adjustment in the use of definite markers when introducing the story characters.</div></div><div><h3>Conclusions</h3><div>While some group differences emerged, people with SZ were generally sensitive to the manipulation regarding their interaction partner's likely knowledge of the characters. A better understanding of the conditions in which speech production is affected in SZ could help promote more efficient communication.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100343"},"PeriodicalIF":2.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurocognitive dysfunctions in childhood-onset schizophrenia: A systematic review","authors":"A. Armita ,&nbsp;J. Guivarch ,&nbsp;E. Dor ,&nbsp;G. Laure ,&nbsp;R. Zeghari ,&nbsp;M. Gindt ,&nbsp;S. Thümmler ,&nbsp;F. Askenazy ,&nbsp;A. Fernandez","doi":"10.1016/j.scog.2024.100342","DOIUrl":"10.1016/j.scog.2024.100342","url":null,"abstract":"<div><h3>Objective</h3><div>To conduct a systematic review of neurocognitive dysfunctions in patients with childhood-onset schizophrenia (COS), a neuropsychiatric disorder that occurs before age 13 and is rarer and more severe than adult-onset schizophrenia.</div></div><div><h3>Method</h3><div>A search was made in the PubMed database. Sixty-seven studies (out of 543) which analyzed Intellectual Quotient (IQ), attentional, memory and executive functions were selected by two independent researchers. Study's appraisal was done according to the Mixed Methods Appraisal Tool (MMAT). This systematic review was registered on PROSPERO (CRD42024548945).</div></div><div><h3>Result</h3><div>COS shows neurocognitive dysfunction in IQ with mean scores ranging from one to two standard deviation lower than normative data. Attentional deficits are observed with longer reaction time, more errors of omission and commission and slower processing speed than controls. In addition, working memory and executive functions, such as planification and flexibility are impaired. COS exhibit significantly more neurocognitive deficits than adolescent and adult-onset forms and display deterioration in intellectual functioning between premorbid period and after onset of psychosis.</div></div><div><h3>Conclusion</h3><div>COS is characterized by major cognitive impairments, both before the onset of the disease and throughout its course. As in adult-onset schizophrenia, generalized cognitive impairment is found without the emergence of a specific profile, providing further support for the continuum hypothesis between early-onset and adult-onset schizophrenia. Collaborative research on a larger scale (including meta-analyses) and using complementary approaches (dimensional and multimodal) is needed to gain a better understanding of the cognitive impact of COS and pave the way for more precise and targeted cognitive remediation.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100342"},"PeriodicalIF":2.3,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ecological validity in cognitive assessment and treatment","authors":"Kathryn E. Lewandowski","doi":"10.1016/j.scog.2024.100341","DOIUrl":"10.1016/j.scog.2024.100341","url":null,"abstract":"","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100341"},"PeriodicalIF":2.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia","authors":"Philip D. Harvey ,&nbsp;Sean McDonald ,&nbsp;Eric Fu ,&nbsp;Corey Reuteman-Fowler","doi":"10.1016/j.scog.2024.100340","DOIUrl":"10.1016/j.scog.2024.100340","url":null,"abstract":"<div><div>Despite significant patient burden, there are no approved pharmacotherapies to treat symptoms of cognitive impairment associated with schizophrenia (CIAS). This double-blind, placebo-controlled, parallel-group Phase II trial assessed the efficacy and safety of pharmacological augmentation of at-home computerized cognitive training (CCT) with iclepertin (BI 425809, a glycine transporter-1 inhibitor). Participants with schizophrenia (aged 18–50 years) on stable antipsychotic therapy, who were compliant with CCT during the run-in period, were enrolled. Patients were randomized (1:1) to once daily iclepertin 10 mg or placebo for 12 weeks, and all patients completed adjunctive CCT. At Week 12, the change from baseline in neurocognitive composite T-score of the MATRICS Consensus Cognitive Battery (primary endpoint), Schizophrenia Cognition Rating Scale interviewer total score, and Positive and Negative Syndrome Scale total score (secondary endpoints) were assessed. Performance was also assessed using Virtual Reality Functional Capacity Assessment Tool adjusted total time T-score. Of 200 randomized patients, 154 (77.0 %) completed the trial. At efficacy endpoint assessment, no differences were observed between treatment groups. Adverse events (AEs) were reported by 39 patients in the iclepertin 10 mg + CCT group and 57 patients in the placebo + CCT group; most AEs were mild to moderate. To our knowledge, this trial is the largest of its kind combining daily pharmacotherapy for CIAS with at-home CCT. Although efficacy was not demonstrated, the safety profile of iclepertin 10 mg was consistent with previous studies and no new risks were identified.</div></div><div><h3>Clinical trial registration</h3><div><span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> identifier: <span><span>NCT03859973</span><svg><path></path></svg></span></div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"40 ","pages":"Article 100340"},"PeriodicalIF":2.3,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of dual-target rTMS over dorsolateral prefrontal cortex (DLPFC) and cerebellum in the treatment of negative symptoms in first-episode schizophrenia: Protocol for a multicenter, randomized, double-blind, sham-controlled study","authors":"Junjie Wang ,&nbsp;Yanyan Wei ,&nbsp;Qiang Hu ,&nbsp;Yingying Tang ,&nbsp;Hongliang Zhu ,&nbsp;Jijun Wang","doi":"10.1016/j.scog.2024.100339","DOIUrl":"10.1016/j.scog.2024.100339","url":null,"abstract":"<div><h3>Background and objective</h3><div>The dorsolateral prefrontal cortex (DLPFC) - cerebellum circuit has been implicated in the pathogenesis of negative symptoms of schizophrenia (SZ). Both areas are considered separate targets for repetitive transcranial magnetic stimulation (rTMS) treatment, showing potential for improving negative symptoms. However, there is still a lack of research that targets both DLPFC and cerebellum simultaneously. In this study, we will explore the efficacy and safety of dual-target rTMS based on the DLPFC-cerebellum circuit in the treatment of negative symptoms in SZ.</div></div><div><h3>Methods</h3><div>The study is a multicenter randomized, double-blind, and sham-controlled trial. First-episode schizophrenia is treated with adjunctive 1 Hz rTMS to the right DLPFC and intermittent theta burst stimulation (iTBS) to the cerebellum delivered sequentially in 20 sessions (active group) or a sham condition (sham group) along with antipsychotics. Clinical symptoms are assessed using the Positive and Negative Symptom Scale (PANSS) at baseline (T0), at the middle of the TMS intervention (after 10 sessions, T1), at the end of the intervention (after 20 sessions, T2), and at a 4-week follow-up after the intervention concludes (T3). Subjects will undergo magnetic resonance imaging (MRI) scans twice: once at baseline (T0) and again at the end of TMS intervention (T2). Comparisons of improvements in negative symptoms are conducted between the active and sham groups. Alterations in functional connectivity (FC) are also compared between both groups. Pearson or Spearman correlation analysis is performed to estimate the relationship between FC alteration and clinical symptom remission (PANSS negative subscale reduction scores and response rates, etc) depending on whether the data follows a normal distribution. In addition, potential neuroimaging biomarkers based on MRI associated with TMS treatment will be explored.</div></div><div><h3>Discussion</h3><div>Positive results from this double-blind, sham-controlled, randomized study may optimize the TMS treatment strategy for SZ, particularly in managing negative symptoms. Clinicians can select TMS with increased confidence as a safe adjunctive treatment option. Furthermore, the findings of this trial may offer preliminary insights into the potential neuroimaging therapeutic mechanisms of TMS interventions targeting the prefrontal-cerebellar circuit.</div><div>Trial registration: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> <span><span>NCT04853485</span><svg><path></path></svg></span></div><div>Primary sponsor: Jijun WANG (J. Wang), Principal Investigator: <span><span><span>[email protected]</span></span><svg><path></path></svg></span></div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"39 ","pages":"Article 100339"},"PeriodicalIF":2.3,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive functioning and functional ability in women with schizophrenia and homelessness","authors":"Jayakumar Menon ,&nbsp;Suvarna Jyothi Kantipudi ,&nbsp;Aruna Mani ,&nbsp;Rajiv Radhakrishnan","doi":"10.1016/j.scog.2024.100338","DOIUrl":"10.1016/j.scog.2024.100338","url":null,"abstract":"<div><h3>Background</h3><div>Studies of schizophrenia and homelessness are minimal from the Indian subcontinent. Women with schizophrenia and homelessness in India remain a highly vulnerable group and there is no data to date regarding their clinical characteristics. Cognitive impairment in schizophrenia remains a major factor determining outcomes in schizophrenia. We examined the cognitive functioning of women with schizophrenia and homelessness (WSH) and compared it to an age-matched group of women with schizophrenia living with their family (WSF).</div></div><div><h3>Methods</h3><div>36 women with schizophrenia and homelessness, and 32 women with schizophrenia who were living with family were evaluated for psychopathology using Scale for Assessment of Positive Symptoms (SAPS)/ Scale for assessment of negative symptoms (SANS) scales. Cognitive function was assessed using Montreal Cognitive Assessment (MOCA)/Rowland Universal Dementia Scale (RUDAS), and Frontal Assessment Battery (FAB), disability using World Health Organization - Disability assessment Scale (WHO-DAS) and psychosocial factors using a semi-structured proforma. The groups were compared using <em>t</em>-tests and chi-square for continuous and categorical variables respectively.</div></div><div><h3>Results</h3><div>Women with schizophrenia and homelessness were found to have significantly lower cognitive functioning, and much higher disability. Cognition and disability for women with schizophrenia and homelessness differed by 2–3 standard deviations with the mean for women living with family (i.e. z scores). Women with schizophrenia experiencing homelessness (WSH group) exhibited higher literacy levels and previous work experience compared to their counterparts. Those with family support are likely to face reduced pressures to work or earn, which further suggests that premorbid levels of functioning may not be the primary factors influencing the differences observed in cognitive assessments.</div></div><div><h3>Conclusions</h3><div>The study demonstrates significantly higher cognitive dysfunction in women with homelessness and schizophrenia, raising the possibility of much higher cognitive dysfunction being a predictor for homelessness in Indian women with schizophrenia.</div></div>","PeriodicalId":38119,"journal":{"name":"Schizophrenia Research-Cognition","volume":"39 ","pages":"Article 100338"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142659060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}